pharmaphorum

AUGUST 6, 2021

There was a dramatic increase in the launch of health-related mobile applications last year, taking the total number on offer in app stories to 350,000 – and while average quality is currently “middling” it is on the rise, according to a report from IQVIA. The pandemic contributed to another 90,000 apps being introduced in 2020 – an average of 250 per day – and this coupled with rising number and functionality of wearable devices “provides evidence of digital health’s acc

145

145

Outsourcing Pharma

AUGUST 5, 2021

A leader from the clinical research tech specialist explains how the use of AI is increasing in the field and outlines the many ways it could SOMETHING.

145

145

Fierce Healthcare

AUGUST 31, 2021

Hospitals stopped suing patients for unpaid medical debt after media exposure, public pressure, study suggests. dmuoio. Tue, 08/31/2021 - 17:13.

Hospitals 138

Hospitals 138

Pharma Marketing Network

AUGUST 18, 2021

SAVE THE DATE – PMN Fall 2021 Summit: Pharma-Marketing Innovations & Trends of 2021 | SEP. 16th, 12:00PM – 1:30PM EST. SAVE YOUR SEAT TODAY. Telehealth: Is It Here to Stay? Once considered a novelty, over the past 18 months, Telehealth has risen to a prominent position in the continuum of care. Pharmaceutical brands must adapt to this new modality and pivot their promotional efforts to ensure that they can leverage the Telehealth channel effectively.

98

98

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharma Times

AUGUST 4, 2021

Sativex is a complex botanical formulation that contains the principal cannabinoids THC and CBD

63

63

pharmaphorum

AUGUST 4, 2021

Spinal Muscular Atrophy (SMA) is a rare disease affecting the motor nerve cells in the spinal cord. It’s a debilitating condition that affects 1 per 8,000 to 10,000 people worldwide , impacting their ability to walk, eat, and breathe. SMA Type 1 represents an estimated 50% of all cases, for which life expectancy is less than 18 months without treatment. .

Patient Care 145

Patient Care FDA 145

pharmaphorum

AUGUST 16, 2021

UK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed second-round financing that will help fund clinical development of its psilocybin-based therapies. The Oxford-based company had originally hoped to raise $50 million from the series B, and the scale of the financing is further evidence that repurposing psychedelic compounds as potential therapies for neuro-psychiatric disorders is a hot topic in biopharma.

Compounding 135

Compounding 135

pharmaphorum

AUGUST 10, 2021

Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. On the firm’s second-quarter results call, Obenshain said the biotech will start “an orderly wind-down” of its activities in Europe and seek “strategic alternatives” to make its therapies available to patients there

FDA 135

FDA 135

pharmaphorum

AUGUST 31, 2021

Fitness wearable company Whoop has raised another $200 million in funding that will help fund its expansion into international markets – and take on deep-pocketed rivals like Amazon, Apple and Google. The sixth-round financing was led by SoftBank’s Vision Fund 2, taking the total raised by the company to date to around $400 million, and catapults Whoop’s valuation to a massive $3.6 billion.

129

129

pharmaphorum

AUGUST 16, 2021

Health Canada has started a rolling review of Merck & Co’s molnupiravir, an oral antiviral therapy treatment for COVID-19 partnered with Ridgeback Biotherapeutics. The Canadian regulator will start reviewing early safety, quality and efficacy data for the drug while late-stage clinical trials are still underway, in the hope of approving the drug quickly of results are positive.

Hospitals 128

Hospitals Vaccines FDA 128

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

AUGUST 24, 2021

Digital health startup Breathe Well-being has raised $5.5 million in first-round financing, which it will use to scale up its clinical tool that it says helps people “prevent, manage and reverse type 2 diabetes.” . The Series A – led by US venture capital group Accel with participation from General Catalyst and Scott Shleifer, global managing director of hedge fund Tiger Global, which is a highly active investor in privately-held tech firms.

126

126

pharmaphorum

AUGUST 5, 2021

Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. The issue, however, is developing an effective way of targeting them. . The latest advancements in methods targeting PPIs are designed to overcome the challenges limiting the conventional methods. Targeting PPIs offers another potential therapeutic target for diseases with complex biological profiles.

Compounding 125

Compounding Chemotherapy 125

pharmaphorum

AUGUST 19, 2021

Novartis’ Rydapt has become the first and only licensed treatment for rare and life-threatening blood disorder systemic mastocytosis (SM) to be cleared for routine NHS use, after getting a green light from NICE. The decision means around 170 people with advanced SM in England and Wales will be eligible for treatment with oral, twice-daily drug, which since 2018 has also been cleared for NHS treatment of a form of acute myeloid leukaemia.

124

124

Outsourcing Pharma

AUGUST 9, 2021

Nanomeâs virtual reality tech is being put to use by Oak Ridge National Laboratory and top pharma firms to study COVID-19 and explore drug candidates.

135

135

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

AUGUST 26, 2021

A merger between two digital mental health companies – Headspace and Ginger – will create a $3 billion giant in a category that has been growing at breakneck speed as a result of the COVID-19 pandemic. The deal brings together Headspace’s meditation and mindfulness app – used by millions of people around the world – and Ginger’s platform which provides therapy and psychiatric support as an on-demand, video-based service.

122

122

Outsourcing Pharma

AUGUST 3, 2021

A leader from the company says to ensure medicines keep reaching the patients that need them, the industry must revamp outdated technologies and techniques.

130

130

Outsourcing Pharma

AUGUST 30, 2021

A leader from the rare and infectious disease treatment specialist talks about ongoing research into a potential treatment for mild-to-moderate COVID-19.

131

131

Outsourcing Pharma

AUGUST 3, 2021

The Psychae Institute, established by a global team of scientists, will conduct pre-clinical and clinical research around psychedelic medicine development.

130

130

Fierce Healthcare

AUGUST 20, 2021

Google says health projects will continue even as it unwinds dedicated health division. hlandi. Fri, 08/20/2021 - 19:08.

145

145

Fierce Healthcare

AUGUST 23, 2021

KFF: Preventable COVID hospitalizations among unvaccinated cost U.S. health system $2.3B. dmuoio. Mon, 08/23/2021 - 16:01.

Hospitals 143

Hospitals 143

Fierce Healthcare

AUGUST 26, 2021

Alphabet's Verily, Mayo Clinic team up on decision support tech for cardiovascular care. hlandi. Thu, 08/26/2021 - 09:08.

Mayo Clinic 143

Mayo Clinic 143

Fierce Healthcare

AUGUST 4, 2021

U.S. ranks last among 10 other countries in new study on healthcare systems. agliadkovskaya. Wed, 08/04/2021 - 10:27.

145

145

pharmaphorum

AUGUST 17, 2021

Rapid advances in the use of artificial intelligence (AI) in healthcare and medicines development are at risk of outstripping current regulatory frameworks, according to a new report. The International Coalition of Medicines Regulatory Authorities (ICMRA) has recommended that a new permanent working group be set up to keep tabs on the use of AI and make sure that regulations can accommodate new developments.

Documentation 116

Documentation Pharmaceutical Companies Pharmaceutical Companies FDA 116

pharmaphorum

AUGUST 10, 2021

Oxford University and UK clinical artificial intelligence (AI) company Sensyne Health will partner on a project to find new drug targets for people with hard-to-treat asthma. It’s estimated that almost one in five people with asthma find it difficult to control symptoms using current therapies, while around 4% have particularly severe forms that puts them at risk of life-threatening attacks.

Hospitals 116

Hospitals 116

Fierce Healthcare

AUGUST 25, 2021

Three-quarters of employers have accelerated telehealth offerings amid pandemic: Business Group. pminemyer. Wed, 08/25/2021 - 16:29.

135

135

pharmaphorum

AUGUST 10, 2021

BioNTech has suggested that giving booster doses of its current Comirnaty (BNT162b2) COVID-19 vaccine may be a preferable strategy to modifying the Pfizer-partnered shot. The comments came on the German biotech’s second-quarter results call, during which BioNTech raised its forecasts for revenues it will book from sales of the vaccine to €15.9 billion (almost $19 billion), on the back of contracts to deliver 2.2 billion doses this year with more than 1 billion already booked in for 2022.

Vaccines 114

Vaccines Immunization 114

Fierce Healthcare

AUGUST 29, 2021

AppliedVR taps Curebase to run at-home clinical trials testing VR for pain treatment. hlandi. Sun, 08/29/2021 - 20:50.

141

141

Fierce Healthcare

AUGUST 30, 2021

Federal judge grants final approval of $575M settlement against Sutter Health. rking. Mon, 08/30/2021 - 13:13.

145

145

Fierce Healthcare

AUGUST 19, 2021

Physician pay remained stagnant while productivity slumped in 2020, new survey finds. agliadkovskaya. Thu, 08/19/2021 - 19:00.

136

136

Fierce Healthcare

AUGUST 18, 2021

Biden administration to invest $19M to expand telehealth in rural, underserved areas. hlandi. Wed, 08/18/2021 - 08:15.

138

138

Fierce Healthcare

AUGUST 9, 2021

New survey finds COVID-19 is taking a significant toll on physicians. agliadkovskaya. Mon, 08/09/2021 - 15:51.

143

143

pharmaphorum

AUGUST 15, 2021

In the latest episode of the podcast Dominic Tyer speaks with Dr Maria Ines ‘Mari’ Mitrani, chief science officer at the clinical-stage biopharmaceutical company Organicell Regenerative Medicine. They looked at the development of regenerative medicine and where Organicell hopes to add to that field. Then, with the company pivoting to try and help tackle Covid, they also discussed how that change was made possible and where Organicell’s focus will be.

111

111

pharmaphorum

AUGUST 9, 2021

AstraZeneca’s Forxiga has become the first SGLT2 inhibitor to be approved in Europe for use in people with chronic kidney disease, extending its lead over rival drugs in the class. The European Commission has cleared Forxiga (dapagliflozin) for CKD in adults with or without diabetes, and the drug becomes the first new drug treatment for these patients in more than two decades.

FDA 111

FDA 111

pharmaphorum

AUGUST 12, 2021

With advertisers preparing to spend up to $15 billion on influencer marketing by 2022, pharmaceutical and biotech companies are increasingly (and carefully) engaging trusted health social influencers to connect more authentically with consumers. As pharma starts to leverage a multitude of high-engagement channels like influencer marketing, online communities and virtual health services, the industry finds itself in a unique position to reimagine traditional direct-to-consumer (DTC) efforts and p

Communication 111

Communication 111